{"product_id":"p53-adenovirus-ad-p53-gfp-bhv21600040","title":"p53 Adenovirus (Ad-p53-GFP)","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eAd-p53-GFP is a replication-defective recombinant Ad5 adenovirus expressing the GFP reporter gene under the p53 promoter. Reporter adenoviruses are commonly used to benchmark transduction efficiency, titrate MOI in new cell or animal models, and as transduction-load controls for paired over-expression vectors.\u003c\/p\u003e\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eBackbone:\u003c\/strong\u003e Human adenovirus type 5 (Ad5) with E1 and E3 deleted (dE1\/E3). Replication-incompetent in standard cells; replication-competent helper cells (HEK293) are required for amplification.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePromoter (p53):\u003c\/strong\u003e a p53-responsive promoter element.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTransgene:\u003c\/strong\u003e GFP (eGFP tag).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTiter \u0026amp; format:\u003c\/strong\u003e 1×10\u003csup\u003e10\u003c\/sup\u003e PFU\/ml in storage buffer (DMEM, 2% BSA, 2.5% glycerol or equivalent), supplied as a 200 µL aliquot.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003eThe widely studied p53 tumor suppressor gene contains mutations in over 50% of human cancers. p53 protein expression is low in normal cells but increases in response to DNA damage and cellular distress signals. Overexpression of the p53 transcription factor can induce either cell cycle arrest or apoptosis through transcriptional regulation of several genes, including the cell cycle inhibitor p21, DNA repair gene GADD45 and the apoptotic inducer Bax. p53 also induces apoptosis by means of a direct signaling pathway involving the expression of p53AIP1. p53 directly binds to and acts on several cellular proteins involved in various pathways, including c-Abl, basal transcription factor TFIIH and WT1. p53 can be functionally inactivated by mutation, binding to DNA tumor virus encoded proteins, such as SV40 large T antigen, Adenovirus E1B and papilloma virus E6 proteins, or through its interaction with MDM2.\u003c\/p\u003e\u003cp\u003eThis adenovirus express both human p53 and GFP.\u003c\/p\u003e\u003cp\u003eReference: Yu J., et al., PNAS (1999) 96: 14517; Chan TA., et al., Genes Dev (00) 14:1584\u003c\/p\u003e\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eUsed in oncology research to model gain-of-function or loss-of-function alterations in tumor-relevant pathways.\u003c\/li\u003e\n\u003cli\u003eAdenoviral delivery enables high-efficiency transduction of cancer cell lines and primary tumor cells.\u003c\/li\u003e\n\u003cli\u003eDecision-relevant for researchers studying p53 Pathway.\u003c\/li\u003e\n\u003cli\u003eAdenovirus-mediated delivery is well-established in primary cells, organoids, and small-animal models.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eTransduction-efficiency benchmarking in new cell lines or animal models.\u003c\/li\u003e\n\u003cli\u003eMOI titration as a positive control before switching to a transgene of interest.\u003c\/li\u003e\n\u003cli\u003ePromoter-activity readout for transcriptional studies.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eAdenoviral delivery is episomal and non-integrating; expression dilutes with cell division and typically lasts 1–2 weeks in dividing cells (longer in non-dividing cells such as hepatocytes, neurons, and cardiomyocytes).\u003c\/li\u003e\n\u003cli\u003ePre-existing anti-Ad5 neutralizing antibodies are common in human and primate hosts and can reduce in vivo transduction; this is less relevant in inbred laboratory mouse strains.\u003c\/li\u003e\n\u003cli\u003eMOI optimization is essential — over-dosing can cause cytopathic effects; under-dosing yields incomplete transduction. A 3–5× MOI titration in your specific cell or animal model is recommended.\u003c\/li\u003e\n\u003cli\u003eReplication-defective Ad5 vectors are typically handled at BSL-2; consult your institutional biosafety officer for specific transgenes and routes of use.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c!-- Sources (internal):\n  - NCBI Gene: https:\/\/www.ncbi.nlm.nih.gov\/gene\n  - UniProt: https:\/\/www.uniprot.org\/\n  - Russell WC. Adenoviruses: update on structure and function. J Gen Virol 2009; 90:1–20.\n  - Alba R, Bosch A, Chillon M. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther 2005; 12 Suppl 1:S18–27.\n  - Vendor reference: https:\/\/www.vectorbiolabs.com\/product\/1260-p53-adenovirus\/\n--\u003e","brand":"Vector Biolabs","offers":[{"title":"1x10^10 PFU\/ml \/ 200 µL","offer_id":53286488899949,"sku":"1260","price":475.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.ebiohippo.com\/products\/p53-adenovirus-ad-p53-gfp-bhv21600040","provider":"BioHippo","version":"1.0","type":"link"}